Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
All news
(page 15)
9 June 2026
GSK to acquire Nuvalent for $10.6 billion
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
9 June 2026
Technip Energies, Airbus, Safran and Tereos form Rebound JV to build 160,000 t/y Alcohol‑to‑Jet SAF at Dunkirk
JV to develop a 160,000 t/y Alcohol‑to‑Jet SAF plant at Port of Dunkirk; partners will fund development, run pre‑FEED/FEED and seek FID after permitting, feedstock and offtake agreements.
9 June 2026
PTT Global Chemical positions Map Ta Phut as regional hub for high‑value, low‑carbon businesses with Toray and Mitsubishi
Turning agricultural residues into bio‑based chemicals; trialled at 50,000‑L fermentation scale; pilot‑scale bio muconic and adipic acid targeted by 2028; pathway to 100% bio‑based nylon 6,6 and expanded market access.
8 June 2026
Gas Malaysia, Tokyo Gas and VTTI to develop 6 MTPA FSRU regasification terminal in Yan, Kedah
Offshore FSRU regasification terminal proposed off Pulau Bunting to add an LNG entry point in northern Peninsular Malaysia; capacity up to 6 MTPA and estimated cost RM2–3bn; project advancing toward FID.
8 June 2026
Honeywell reaffirms 2026 guidance and issues Honeywell Technologies outlook
Full-year sales $38.8–39.8B; adjusted EPS $10.35–10.65 and free cash flow $5.3–5.6B. Post-spin Honeywell Technologies sales $19.9–20.2B; adjusted EPS $3.95–4.15.
8 June 2026
Honeywell expands OT Cybersecurity Suite with AI monitoring and secure media controls
Adds five OT security capabilities — AI monitoring, secure media scanning, data diode, Cyber GRC automation and a managed OT SOC — for manufacturing, energy and critical infrastructure.
News type
Project Updates and Milestones
New Projects and Expansions
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Operational Changes and Investments
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
8 June 2026
Braskem brings IG4 and Petrobras into governance and names new executive team
Governance refreshed to accelerate financial reorganisation, improve operational efficiency and preserve liquidity; new CEO and turnaround-focused leadership appointed.
8 June 2026
Uniper and Ksi Lisims LNG sign LOI for 2 mtpa Canadian LNG supply
LOI outlines a 2 mtpa long-term LNG purchase, with first volumes possible in 2032 from a proposed 12 mtpa BC floating export facility designed for low emissions.
8 June 2026
Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials
Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
8 June 2026
Gilead and Merck: Phase 3 ISLEND trials show positive topline results for once‑weekly islatravir/lenacapavir
Once‑weekly oral islatravir 2 mg/lenacapavir 300 mg met Week 48 primary endpoint, non‑inferior to Biktarvy and daily standard‑of‑care; safety profile comparable across arms.
8 June 2026
Merck and Gilead discontinue Phase 3 KEYNOTE‑D46/EVOKE‑03 (Trodelvy + KEYTRUDA) in PD‑L1 ≥50% mNSCLC
eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.
8 June 2026
Meccanoplastica showcases INEOS recycled HDPE at PLAST 2026
Live blow-moulding demo will produce 200ml cosmetic bottles with advanced recycled HDPE; 4L samples use Recycl-IN HDPE with 50% post‑consumer recyclate to support regulatory targets.
8 June 2026
Equinor ASA elects Jarle Roth as board chair
Jarle Roth named chair; deputy and several board members re-elected; new board term runs 1 July 2026 to June 2027.
8 June 2026
Iberdrola (Neoenergia) to invest €4.5bn in Bahia power networks to 2030
Nearly €4.5bn (25bn reais) planned for Bahia to 2030 to expand, modernise and digitalise networks and connect new industries with 54 substations and extensive HV/MV lines.
8 June 2026
PPG appoints John Smith VP, Architectural Coatings EMEA; Steve Pocock to retire
John Smith will lead EMEA architectural coatings from July 1, 2026; Steve Pocock retires June 30, 2026.
8 June 2026
Johnson & Johnson to acquire Firefly Bio for $1 billion to add Firelink DAC platform
Targets KRAS-driven solid tumours with a selective protein degrader; closing expected later this year pending regulatory approvals.
8 June 2026
WACKER: ceramifying silicone and 1.6/2.4 W/mK potting compounds for BEV thermal protection
Ceramifying silicone boosts thermal and flame resistance in battery barriers; potting compounds deliver 1.6 and 2.4 W/mK, low sedimentation and room‑temperature cure.
8 June 2026
PETRONAS and Eni form Searah JV to boost regional energy security
50:50 JV combines 19 gas assets across Malaysia and Indonesia, targets 300k→500k boe/d and plans $20bn investment backed by a $6bn credit facility.
8 June 2026
Siemens and Infineon partner to add CoolSiC SiC modules to SENTRON 3QD2 breakers
SiC power modules boost semiconductor circuit breakers for faster, denser, more reliable protection in data centers, factories and battery storage.
8 June 2026
Technip Energies wins EPCIC contract for Coral Norte FLNG with JGC and Samsung Heavy
Coral Norte FLNG will produce ~3.6 Mtpa, doubling the Coral hub to 7 Mtpa and placing Mozambique among Africa’s top three LNG producers.
8 June 2026
ORLEN launches small‑scale LNG and bioLNG market demand survey
Survey collects customer forecasts on volumes, delivery points and fuel-use models to shape future small‑scale LNG/bioLNG infrastructure and commercial offers; open until end of June.
8 June 2026
Aurubis Italia first site in Italy awarded The Copper Mark
Avellino rod plant becomes first in Italy to gain The Copper Mark, completing certification of all four rod plants and expanding verified coverage across the group's production network.
8 June 2026
BASF launches Oppanol® N PLUS binder for next‑generation EV batteries
High‑spec polyisobutene binder for solid‑state and advanced EV batteries; narrow specs reduce production variability; fresh stock and 20 kg packaging support OEMs.
8 June 2026
Kemira: Nomination Board members named
Four largest shareholders — Oras Invest, Varma, Ilmarinen and Nordea Funds — appoint representatives to the Nomination Board; Board Chair serves as expert member.
8 June 2026
Roche and Nurix partner to co-develop and co-commercialise BTK degrader bexobrutideg
Collaboration targets B‑cell malignancies, immunology and neurology with an oral, brain‑penetrant BTK degrader planned for Phase 3 in summer 2026.
8 June 2026
AGC Biologics to develop and manufacture KTP-001 (rhMMP-7) for Teikoku Pharma
Microbial process development and GMP clinical manufacturing of rhMMP‑7 for intradiscal injection; cell bank moved from Heidelberg to Chiba; intended as a lumbar disc herniation treatment.
7 June 2026
Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
7 June 2026
Novo Nordisk CagriSema Phase 3 trials show large HbA1c and weight reductions
Once‑weekly cagrilintide+semaglutide reduced HbA1c by up to 2.33 percentage points and bodyweight by up to 14.2% across REIMAGINE 1–3 versus comparators.
7 June 2026
Lilly Foundayo shows weight loss across pre-, peri- and post‑menopause
Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.
7 June 2026
Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
← Previous
Next →